CARDIOVASCULAR JOURNAL OF AFRICA • Volume 25, No 3, May/June 2014
140
AFRICA
Eur Heart J
2008;
29
: 932–940.
9.
Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular
disease in Europe: epidemiological update.
Eur Heart J
2013;
34
:
3028–3034.
10. Kim HC, Greenland P, Rossouw JE,
et al
. Multimarker prediction of
coronary heart disease risk: The Women’s Health Initiative.
J Am Coll
Cardiol
2010;
55
: 2080–2091.
11. Perk J, De Backer G, Gohlke H,
et. al
. Developed with the special
contribution of the European Association for Cardiovascular Prevention
& Rehabilitation (EACPR). European guidelines on cardiovascular
disease prevention in clinical practice (version 2012): the fifth joint
task force of the European society of cardiology and other societies
on cardiovascular disease prevention in clinical practice (constituted
by representatives of nine societies and by invited experts).
Eur J Prev
Cardiol
2012;
19
: 585–667.
12. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM.
Statins for the primary prevention of cardiovascular events in women
with elevated high-sensitivity C-reactive protein or dyslipidemia:
results from the Justification for the Use of statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-
analysis of women from primary prevention trials.
Circulation
2010;
121
: 1069–1077.
13. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM.
Interrelationships among circulating interleukin-6, C-reactive protein,
and traditional cardiovascular risk factors in women.
Arterioscler
Thromb Vasc Biol
2002;
22
: 1668–1673.
14. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive
protein in cardiovascular risk prediction models for women.
Ann Intern
Med
2006;
145
: 21
–
29.
15. Shaw LJ, Bairey Merz CN, Azziz R,
et al
. Postmenopausal women with
a history of irregular menses and elevated androgen measurements at
high risk for worsening cardiovascular event-free survival: results from
the National Institutes of Health – National Heart, Lung, and Blood
Institute sponsored Women’s Ischemia Syndrome Evaluation.
J Clin
Endocrinol Metab
2008;
93
: 1276–1284.
16. Stangl V, Baumann G, Stangl K. Coronary atherogenic risk factors in
women.
Eur Heart J
2002;
23
:1738–1752.
17. Mitu F, Pop D, Zdrenghea D.
Particularit
ăţ
i ale bolilor cardiovascu-
lare la femei
. Ed. Clusium. Cluj-Napoca, 2012.
18. Fraser A, May M, Lowe G,
et al
. Interleukin-6 and incident coronary
heart disease: results from the British Women’s Heart and Health
Study.
Atherosclerosis
2009;
202
: 567–572.
19. Danesh J, Kaptoge S, Mann AG,
et al
. Long-term interleukin-6 levels
and subsequent risk of coronary heart disease: two new prospective
studies and a systematic review.
PLoS Med
2008;
5
: 78.
20. Lowe GD. Circulating inflammatory markers and risks of cardio-
vascular and non-cardiovascular disease.
J Thromb Haemost
2005;
3
:1618–1627.
21. Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G. A
comparison of the associations between seven hemostatic or inflam-
matory variables and coronary heart disease.
J Thromb Haemost
2007;
5
:1795–1800.
22. Danesh J, Lewington S, Thompson SG,
et al
. Plasma fibrinogen level
and the risk of major cardiovascular diseases and nonvascular mortal-
ity: an individual participant meta-analysis.
J Am Med Assoc
2005;
294
:1799–1809.
23. Rossouw JE, Cushman M, Greenland P,
et al.
Inflammatory, lipid,
thrombotic, and genetic markers of coronary heart disease risk in the
Women’s Health Initiative trials of hormone therapy.
Arch Intern Med
2008;
168
: 2245–2253.
24. Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G. A
comparison of the associations between seven hemostatic or inflam-
matory variables and coronary heart disease.
J Thromb Haemost
2007;
5
:1795–1800.
25. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G.
Which hemostatic markers add to the predictive value of conven-
tional risk factors for coronary heart disease and ischemic stroke? The
Caerphilly Study.
Circulation
2005;
112
: 3080–3087.
26. Danesh J, Whincup P, Walker M,
et al.
Fibrin D-dimer and coronary
heart disease: prospective study and meta-analysis.
Circulation
2001;
103
: 2323–2327.
27. Rana JS, Cote M, Després JP,
et al.
Inflammatory biomarkers and
the prediction of coronary events among people at intermediate risk:
the EPIC-Norfolk prospective population study.
Heart
2009;
95
:
1682–1687.
28. Wassertheil-Smoller S, Kooperberg C, McGinn AP,
et al.
Lipoprotein-
associated phospholipase A2, hormone use, and the risk of ischemic
stroke in postmenopausal women.
Hypertension
2008;
51
: 1115–1122.
29. Hatoum IJ, Cook NR, Nelson JJ, Rexrode KM, Rimm EB. Lipoprotein-
associated phospholipase A2 activity improves risk discrimination of
incident coronary heart disease among women.
Am Heart J
2011;
161
:
516–522.
30. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo
B lipoproteins with arterial proteoglycans: pathological significance
and molecular basis.
Atherosclerosis
1998;
139
: 205–222.
31. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E. Phospholipase A(2)
modification of low density lipoproteins forms small high density parti-
cles with increased affinity for proteoglycans and glycosaminoglycans.
J Biol Chem
1999;
274
: 25913–25920.
32. Hakala JK, Oorni K, Pentikainen MO, Hurt-Camejo E, Kovanen PT.
Lipolysis of LDL by human secretory phospholipase A(2) induces
particle fusion and enhances the retention of LDL to human aortic
proteoglycans.
Arterioscler Thromb Vasc Biol
2001;
21
: 1053–1058.
33. Neuzil J, Upston JM, Witting PK, Scott KF, Stocker R. Secretory
phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase-
induced enzymic and nonenzymic lipid peroxidation in low-density
lipoproteins.
Biochemistry
1998;
37
: 9203–9210.
34. Oestvang J, Bonnefont-Rousselot D, Ninio E, Hakala JK, Johansen B,
Anthonsen MW. Modification of LDL with human secretory phospho-
lipase A2 or sphingomyelinase promotes its arachidonic acid-releasing
propensity.
J Lipid Res
2004;
45
: 831–838.
35. Greenland P, Alpert JS, Beller GA,
et al
. 2010 ACCF/AHA guideline
for assessment of cardiovascular risk in asymptomatic adults: a report
of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines.
J Am Coll Cardiol
2010;
56
:50–103.
36. The Atherosclerosis Risk in Communities (ARIC) Study: design
and objectives. The ARIC investigators.
Am J Epidemiol
1989;
129
:
687–702.
37. Rosenson RS, Hurt-Camejo E. Novel therapeutic concepts:
Phospholipase A2 enzymes and the risk of atherosclerosis.
Eur Heart
J
2012;
33
: 2899–2909.
38. Burke AP, Farb A, Malcom GT,
et al
. Effect of risk factors on the
mechanism of acute thrombosis and sudden coronary death in women.
Circulation
1998;
97
: 2110–2116.
39. Wang TJ, Gona P, Larson MG,
et al
. Multiple biomarkers for the
prediction of first major cardiovascular events and death.
N Engl J Med
2006;
355
: 2631–2639.
40. Melander O, Newton-Cheh C, Almgren P,
et al
. Novel and conven-
tional biomarkers for prediction of incident cardiovascular events in the
